562 related articles for article (PubMed ID: 15790548)
21. Hemoglobinization and functional availability of iron for erythropoiesis in case of thalassemia and iron deficiency anemia.
Bartels PC; Schoorl M; Schoorl M
Clin Lab; 2006; 52(3-4):107-14. PubMed ID: 16584056
[TBL] [Abstract][Full Text] [Related]
22. [Increased erythron transferrin uptake associated with ineffective erythropoiesis in iron deficiency state--the common factors to iron deficiency anemia and portal hypertensions].
Takahashi Y; Umadome H; Ohno Y
Rinsho Ketsueki; 1998 Jan; 39(1):34-43. PubMed ID: 9492551
[TBL] [Abstract][Full Text] [Related]
23. Anemia in chronic renal disease: evaluation of inflammatory activity on erythropoiesis and iron metabolism in patients not submitted to dialysis treatment.
De Lima GA; Mazzali M; Gentil AF; Plotegher L; Grotto HZ
Clin Lab; 2012; 58(7-8):695-704. PubMed ID: 22997970
[TBL] [Abstract][Full Text] [Related]
24. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
Cowgill LD; James KM; Levy JK; Browne JK; Miller A; Lobingier RT; Egrie JC
J Am Vet Med Assoc; 1998 Feb; 212(4):521-8. PubMed ID: 9491159
[TBL] [Abstract][Full Text] [Related]
25. Effects of subcutaneous recombinant human erythropoietin in normal subjects: development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis.
Brugnara C; Colella GM; Cremins J; Langley RC; Schneider TJ; Rutherford CJ; Goldberg MA
J Lab Clin Med; 1994 May; 123(5):660-7. PubMed ID: 8195672
[TBL] [Abstract][Full Text] [Related]
26. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure.
Opasich C; Cazzola M; Scelsi L; De Feo S; Bosimini E; Lagioia R; Febo O; Ferrari R; Fucili A; Moratti R; Tramarin R; Tavazzi L
Eur Heart J; 2005 Nov; 26(21):2232-7. PubMed ID: 15987710
[TBL] [Abstract][Full Text] [Related]
27. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes.
Parisotto R; Gore CJ; Emslie KR; Ashenden MJ; Brugnara C; Howe C; Martin DT; Trout GJ; Hahn AG
Haematologica; 2000 Jun; 85(6):564-72. PubMed ID: 10870111
[TBL] [Abstract][Full Text] [Related]
28. Serum soluble transferrin receptor in hypochromic microcytic anaemia.
Jayaranee S; Sthaneshwar P
Singapore Med J; 2006 Feb; 47(2):138-42. PubMed ID: 16435056
[TBL] [Abstract][Full Text] [Related]
29. Iron metabolism in rhEPO-treated hemodialysis patients.
Schaefer RM; Bahner U
Clin Nephrol; 2000 Feb; 53(1 Suppl):S65-8. PubMed ID: 10746809
[TBL] [Abstract][Full Text] [Related]
30. Iron metabolism and iron substitution during erythropoietin therapy.
Sunder-Plassmann G; Hörl WH
Clin Investig; 1994; 72(6 Suppl):S11-5. PubMed ID: 7950165
[TBL] [Abstract][Full Text] [Related]
31. Iron deficiency and erythropoiesis: new diagnostic approaches.
Brugnara C
Clin Chem; 2003 Oct; 49(10):1573-8. PubMed ID: 14500582
[TBL] [Abstract][Full Text] [Related]
32. Phlebotomies or erythropoietin injections allow mobilization of iron stores in a mouse model mimicking intensive care anemia.
Lasocki S; Millot S; Andrieu V; Lettéron P; Pilard N; Muzeau F; Thibaudeau O; Montravers P; Beaumont C
Crit Care Med; 2008 Aug; 36(8):2388-94. PubMed ID: 18664788
[TBL] [Abstract][Full Text] [Related]
33. Disorders of iron metabolism. Part II: iron deficiency and iron overload.
Muñoz M; García-Erce JA; Remacha ÁF
J Clin Pathol; 2011 Apr; 64(4):287-96. PubMed ID: 21177268
[TBL] [Abstract][Full Text] [Related]
34. Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function.
Brugnara C
Crit Rev Clin Lab Sci; 2000 Apr; 37(2):93-130. PubMed ID: 10811141
[TBL] [Abstract][Full Text] [Related]
35. Anemia of chronic disease (anemia of inflammation).
Agarwal N; Prchal JT
Acta Haematol; 2009; 122(2-3):103-8. PubMed ID: 19907147
[TBL] [Abstract][Full Text] [Related]
36. Pathophysiology of renal anemia.
Eckardt KU
Clin Nephrol; 2000 Feb; 53(1 Suppl):S2-8. PubMed ID: 10746799
[TBL] [Abstract][Full Text] [Related]
37. [Influence of tumor necrosis factor-alpha and interferon-gamma on erythropoietin production and erythropoiesis in cancer patients with anemia].
Wang W; Zhang MH; Yu Y; Xu CG
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):681-4. PubMed ID: 18399174
[TBL] [Abstract][Full Text] [Related]
38. Discrepancy between the percentage of hypochromic erythrocytes and the reticulocyte hemoglobin content in hemodialysis patients with recombinant human erythropoietin therapy.
Asanuma M; Taguchi C; Uesaka H; Kumagai T; Seino K; Hosokawa H; Yamauchi F; Fujishima M; Murai K; Ishida Y
Lab Hematol; 2005; 11(2):124-30. PubMed ID: 16024336
[TBL] [Abstract][Full Text] [Related]
39. Erythrocyte and reticulocyte indices in the assessment of erythropoiesis activity and iron availability.
Urrechaga E; Borque L; Escanero JF
Int J Lab Hematol; 2013 Apr; 35(2):144-9. PubMed ID: 23033935
[TBL] [Abstract][Full Text] [Related]
40. Reticulocyte hemoglobin equivalent: an indicator of reduced iron availability in chronic kidney diseases during erythropoietin therapy.
Garzia M; Di Mario A; Ferraro E; Tazza L; Rossi E; Luciani G; Zini G
Lab Hematol; 2007; 13(1):6-11. PubMed ID: 17353176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
